A Deep Learning Decision Support Tool to Improve Risk Stratification and Reduce Unnecessary Biopsies in BI-RADS 4 Mammograms

Chika F. Ezeana, Tiancheng He, Tejal A. Patel, Virginia Kaklamani, Maryam Elmi, Erika Brigmon, Pamela M. Otto, Kenneth A. Kist, Heather Speck, Lin Wang, Joe Ensor, Ya Chen T. Shih, Bumyang Kim, I. Wen Pan, Adam L. Cohen, Kristen Kelley, David Spak, Wei T. Yang, Jenny C. Chang, Stephen T.C. Wong

Producción científica: Articlerevisión exhaustiva

1 Cita (Scopus)

Resumen

Purpose: To evaluate the performance of a biopsy decision support algorithmic model, the intelligent-augmented breast cancer risk calculator (iBRISK), on a multicenter patient dataset. Materials and Methods: iBRISK was previously developed by applying deep learning to clinical risk factors and mammographic descriptors from 9700 patient records at the primary institution and validated using another 1078 patients. All patients were seen from March 2006 to December 2016. In this multicenter study, iBRISK was further assessed on an independent, retrospective dataset (January 2015–June 2019) from three major health care institutions in Texas, with Breast Imaging Reporting and Data System (BI-RADS) category 4 lesions. Data were dichotomized and trichotomized to measure precision in risk stratification and probability of malignancy (POM) estimation. iBRISK score was also evaluated as a continuous predictor of malignancy, and cost savings analysis was performed. Results: The iBRISK model’s accuracy was 89.5%, area under the receiver operating characteristic curve (AUC) was 0.93 (95% CI: 0.92, 0.95), sensitivity was 100%, and specificity was 81%. A total of 4209 women (median age, 56 years [IQR, 45–65 years]) were included in the multicenter dataset. Only two of 1228 patients (0.16%) in the “low” POM group had malignant lesions, while in the “high” POM group, the malignancy rate was 85.9%. iBRISK score as a continuous predictor of malignancy yielded an AUC of 0.97 (95% CI: 0.97, 0.98). Estimated potential cost savings were more than $420 million. Conclusion: iBRISK demonstrated high sensitivity in the malignancy prediction of BI-RADS 4 lesions. iBRISK may safely obviate biopsies in up to 50% of patients in low or moderate POM groups and reduce biopsy-associated costs.

Idioma originalEnglish (US)
Número de artículoe220259
PublicaciónRadiology: Artificial Intelligence
Volumen5
N.º6
DOI
EstadoPublished - nov 2023

ASJC Scopus subject areas

  • Artificial Intelligence
  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging

Huella

Profundice en los temas de investigación de 'A Deep Learning Decision Support Tool to Improve Risk Stratification and Reduce Unnecessary Biopsies in BI-RADS 4 Mammograms'. En conjunto forman una huella única.

Citar esto